Abstract
Study objective Sleeve gastrectomy is effective in morbid obesity, and it improves glucose homeostasis. In gastric cancer patients with type 2 diabetes mellitus, gastrectomy, including total gastrectomy (TG), is beneficial for glycaemic control. However, the effects of gastrectomy and different reconstructive techniques on the incidence of postoperative diabetes in gastric cancer patients are unclear. This study investigated the development of new-onset diabetes in these patients, focusing on different reconstruction methods.
Design A comparative study
Setting Electrical medical records
Patients This study included 715 patients without diabetes who underwent TG at Tokyo Metropolitan Bokutoh Hospital between August 2005 and March 2019.
Interventions Patients underwent reconstruction by Roux-en-Y (RY) or other surgical techniques (OT), with diabetes onset determined by HbA1c levels or medical records.
Measurements Analyses included two-sample t-tests, chi-squared tests, and the Kaplan-Meier method with log-rank tests to compare the onset curves between the two groups.
Main Results Stratified data analysis compared the RY and OT reconstruction methods. Log-rank test results (P=0.0217) indicated a statistically significant difference in the incidence of new-onset diabetes between RY and OT groups in gastric cancer patients.
Conclusion This first-of-its-kind study provides insight into how different methods of gastric reconstruction affect postoperative diabetes. The results suggest significant differences in new-onset diabetes mellitus after surgery based on the reconstruction method. This research highlights the need for careful surgical planning to consider potential postoperative diabetes, particularly in patients with a family history of diabetes mellitus. Future studies should investigate the role of gut microbiota and other reconstructive techniques, such as laparoscopic jejunal interposition, in developing postoperative diabetes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Tokyo Metropolitan Bokutoh Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
Data is available upon request to the corresponding author. Codes have been uploaded here https://github.com/bougtoir/gastric_dm
